This is a renewal application for years 20 to 24 of the Georgetown Lombardi Comprehensive Cancer Center (Lombardi) CCSG. Lombardi's mission is to prevent, treat and cure cancers, through cutting-edge research, expert and compassionate patient care, education of future cancer specialists, and service to the community. Lombardi is the only NCI-designated cancer center in the nation's capital and in the Washington metropolitan area. The District of Columbia has among the highest cancer mortality rates in the country. Thus, there is a clear need for an NCI-designated comprehensive cancer center that can bring a targeted, evidence-based strategy to cancer care and prevention to help improve the health of the community's residents. In the present application, Lombardi comprises 177 members (113 full members), participating in six research programs with the support of 12 shared resources, based primarily in two adjacent buildings. Peer-reviewed research annual direct funding for 2008 totaled $53 million, with $28.5 million coming from the NCI. This represents a significant increase in NCI funding compared with 2002. Lombardi clinical activities are carried out in conjunction with GU's clinical partner, MedStar Health, Inc. In FY02, Lombardi clinical services served more than 22,000 outpatient cancer visits, and 603 patients were enrolled on Lombardi clinical trials. Outpatient cancer visits have increased to 39,000 in 2008, with 1,169 people placed on interventional trials. Georgetown University's (GU) unwavering high level of commitment to the success of Lombardi is exemplified by the recruitment of a new Director, Louis Weiner, M.D., in January 2008. He also chairs the GU Department of Oncology, with the authority to recruit faculty, control space, and oversee resource allocation to support Lombardi's mission. Several recent high-profile recruitments attest to Lombardi's ability to attract outstanding researchers. The success of Lombardi's research environment is demonstrated by its six research programs in the areas of basic science, clinical translational research, and population science, coupled with new cross-cutting initiatives in health disparities and systems medicine. Lombardi's researchers published almost 2,000 peer-reviewed manuscripts (24% intraprogrammatic and 22% interprogrammatic) in the current funding period, exerting a sustained and powerful influence on the cancer research fields highlighted in this application, such as the development of human papillomavirus vaccines. With continued CCSG support, Lombardi will continue to make outstanding, high-impact contributions to cancer research.
This is a renewal application for years 20 to 24 of the Georgetown Lombardi Comprehensive Cancer Center (Lombardi) CCSG, led by Louis Weiner, M.D. Lombardi's mission is to prevent, treat and cure cancers, through cutting-edge research, expert and compassionate patient care, education of future cancer specialists, and service to the community. The success of Lombardi's research environment is demonstrated by its six research programs in the areas of basic science, clinical translational research, and population science. Each program brings together cancer researchers who focus on distinct areas, coupled with new cross-cutting initiatives in health disparities and systems medicine. With continued CCSG support, Lombardi will continue to make outstanding, high impact contributions to cancer research.
|Rao, Guanhua; Pierobon, Mariaelena; Kim, In-Kyu et al. (2017) Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep 7:7066|
|Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2017) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother :|
|Vietsch, Eveline E; Graham, Garrett T; McCutcheon, Justine N et al. (2017) Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genet 218-219:39-50|
|Lynce, Filipa; Barac, Ana; Tan, Ming T et al. (2017) SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist 22:518-525|
|Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438|
|Zhang, Yong-Wei; Nasto, Rochelle E; Jablonski, Sandra A et al. (2017) RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio Protoc 7:|
|DeVito, Stephen; Woodrick, Jordan; Song, Linze et al. (2017) Mutagenic potential of hypoxanthine in live human cells. Mutat Res 803-805:9-16|
|Wang, Hongkun; Wang, Ying; Kota, Krishna K et al. (2017) Strong associations between chromosomal aberrations in blood lymphocytes and the risk of urothelial and squamous cell carcinoma of the bladder. Sci Rep 7:13493|
|Parodi, Daniela A; Greenfield, Morgan; Evans, Claire et al. (2017) Alteration of Mammary Gland Development and Gene Expression by In Utero Exposure to Cadmium. Int J Mol Sci 18:|
|Casero, David; Gill, Kirandeep; Sridharan, Vijayalakshmi et al. (2017) Space-type radiation induces multimodal responses in the mouse gut microbiome and metabolome. Microbiome 5:105|
Showing the most recent 10 out of 997 publications